Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for eye care in the United States. Its primary product is XDEMVY, a lotilaner ophthalmic solution approved for treating Demodex blepharitis, a condition caused by Demodex mite infestation. The company also has a pipeline including TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trials for ocular rosacea, and TP-05, an oral tablet formulation in Phase 2 trials for Lyme disease prevention, with additional preclinical studies for community malaria reduction. Tarsus is developing the lotilaner active pharmaceutical ingredient (API) for human medicine applications in eye care and infectious disease prevention.

Tarsus Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol TARS. The company's financial reporting and stock trading are conducted in US Dollars (USD), as it is headquartered in the United States and operates primarily within the US market.

Tarsus Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of innovative therapies, particularly in eye care and infectious disease prevention. Its work involves developing prescription treatments like XDEMVY for Demodex blepharitis and advancing pipeline candidates for conditions such as ocular rosacea and Lyme disease.

Tarsus Pharmaceuticals is headquartered in Irvine, California, United States. The company primarily serves the US market, distributing its products through specialty pharmacies, distributors, clinics, hospitals, pharmacies, and federal healthcare programs. While its main focus is the US, it has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for Demodex blepharitis and meibomian gland disease, indicating potential international expansion.

Tarsus Pharmaceuticals generates revenue primarily through the commercialization of XDEMVY, its approved lotilaner ophthalmic solution for Demodex blepharitis. The product is distributed to specialty pharmacies and distributors, as well as directly to clinics, hospitals, pharmacies, and federal healthcare programs. Additionally, the company has a pipeline of product candidates, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, which may generate future revenue upon approval. Tarsus also has a licensing agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for TP-03 in China, which could provide milestone payments and royalties.